Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin etest for rifamycin resistance

Journal of Clinical Microbiology

Volumn 49, Issue 12, 2011, Pages 4319-4321

  Miller, Mark A ^a   Blanchette, Ruth ^a   Spigaglia, Patrizia ^b   Barbanti, Fabrizio ^b   Mastrantonio, Paola ^b  

^a MCGILL UNIVERSITY   (Canada)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; RIFAMYCIN; RIFAXIMIN;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG MECHANISM; EPSILOMETER TEST; ESCHERICHIA COLI INFECTION; GENE MUTATION; HEPATIC ENCEPHALOPATHY; ITALY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RPOB GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TRAVELLER DIARRHEA;

ANTI-BACTERIAL AGENTS; CANADA; CLOSTRIDIUM DIFFICILE; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; HUMANS; ITALY; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; RIFAMYCINS;

EID: 82455174910     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05100-11     Document Type: Article

References (27)

1. Abramowicz, M. (ed.). 2011. Treatment of Clostridium difficile infection. Med. Lett. Drugs Ther. 53:14-15.
2. Baines, S. D., et al. 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J. Antimicrob. Chemother. 62:1046-1052.
3. Campbell, E. A., et al. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912. (Pubitemid 32289282)
4. Cellai, L., M. Colosimo, E. Marchi, A. P. Venturini, and G. Zanolo. 1984. Rifaximin (L/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats. Chemioterapia (Basel) 3:373-377. (Pubitemid 15165655)
5. Clinical and Laboratory Standards Institute. 2008. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 6th ed. M11-A7. CLSI, Wayne, PA.
6. Curry, S. R., et al. 2009. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin. Infect. Dis. 48:425-429.
7. Fawley, W. N., and M. H. Wilcox. 2002. Pulsed-field gel electrophoresis can yield DNA fingerprints of degradation-susceptible Clostridium difficile strains. J. Clin. Microbiol. 40:3546-3547. (Pubitemid 34977494)
8. Garey, K. W., M. Salazar, D. Shah, R. Rodrigue, and H. L. DuPont. 2008. Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann. Pharmacother. 42:827-835. (Pubitemid 351778089)
9. Hecht, D. W., et al. 2007. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51:2716-2719. (Pubitemid 47206204)
10. Jiang, Z.-D., S. Ke, E. Palazzini, L. Riopel, and H. Dupont. 2000. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother. 44:2205-2206.
11. Jiang, Z.-D., H. L. DuPont, M. La Rocco, and K. W. Garey. 2010. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J. Clin. Pathol. 63:355-358.
12. Koo, H. L., and H. L. Dupont. 2010. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr. Opin. Gastroenterol. 26:17-25.
13. Loo, V. G., et al. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449. (Pubitemid 41770165)
14. Louie, T., M. Miller, M. Donskey, K. Mullane, and E. J. Goldstein. 2009. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob. Agents Chemother. 53:223-228.
15. Louie, T., et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
16. McDonald, L. C., et al. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441. (Pubitemid 41770164)
17. Murphy, C. K., et al. 2006. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50:827-834. (Pubitemid 43327784)
18. Musher, D. M., et al. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590. (Pubitemid 40720807)
19. O'Connor, J. R., et al. 2008. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52:2813-2817.
20. Peláez, T., L., et al. 2002. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob. Agents Chemother. 46:1647-1650.
21. Pépin, J., et al. 2005. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 40:1591-1597. (Pubitemid 40720808)
22. Salix Pharmaceuticals, Ltd. 10 December 2003, posting date. Salix receives FDA notification that rifaximin amendment considered a complete response. Salix Pharmaceuticals, Raleigh, NC. http://www.businesswire.com /news/home/20031210005070/en/Salix-Receives-FDA-Notification-Rifamixin- Amendment-Considered.
23. Salix Pharmaceuticals. 2010. XIFAXAN (rifaximin) 550 mg tablets now available in U.S. pharmacies: new patient and physician assistance program (H.E.L.P.) launches to educate patients and assist with treatment adherence. Salix Pharmaceuticals, Raleigh, NC. http://www.salix.com/news-media/news /news-archive/10-05-24/xifaxan%C2%AE-rifaximin-550-mg-tablets-now -available-in-u-s-pharmacies.aspx.
24. Scarpellini, E., et al. 2007. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 25:781-786. (Pubitemid 46434913)
25. Scarpignato, C., and I. Pelosini. 2005. I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 51(Suppl. 1):36-66. (Pubitemid 40663190)
26. Tenover, F. C., et al. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
27. Wilson, V., et al. 2010. Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom. Clin. Infect. Dis. 50:e77-e81.